Scott Richard Daigle is a prominent inventor based in Newburyport, MA (US). He has made significant contributions to the field of cancer treatment, holding a total of nine patents. His work focuses on innovative methods that target specific mechanisms involved in cancer progression.

Latest Patents

Among his latest patents is a method of treating leukemia. This invention relates to methods for addressing disorders influenced by DOT1L-mediated protein methylation, particularly in cancer. The approach involves administering DOT1L inhibitor compounds and pharmaceutical compositions to patients in need. Another notable patent is the use of EZH2 inhibitors for treating cancer. This disclosure outlines methods for treating and identifying subjects with cancer characterized by upregulated immune checkpoint proteins. The methods include administering a therapeutically effective amount of an EZH2 inhibitor, such as tazemetostat, alongside an immune checkpoint inhibitor.

Career Highlights

Scott Richard Daigle is currently associated with Epizyme, Inc., a company dedicated to developing innovative cancer therapies. His work at Epizyme has positioned him as a key player in the advancement of targeted cancer treatments.

Collaborations

Some of his notable coworkers include Roy MacFarlane Pollock and Edward James Olhava. Their collaborative efforts contribute to the ongoing research and development of effective cancer therapies.

Conclusion

Scott Richard Daigle's innovative work in cancer treatment exemplifies the impact of targeted therapies in modern medicine. His contributions through patents and collaboration with industry professionals continue to advance the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.